/IMV.TO

IMV.TO Stock - IMV Inc.

Q: What is the analyst price target for IMV.TO?

Analyst price target information is not currently available for IMV.TO.

Q: What is IMV.TO's market cap?

Market capitalization information is not currently available for IMV.TO.

Healthcare|Biotechnology|TSX

$1.12+0.00%

+$0.00 (+0.00%) • Apr 28

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1.23

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for IMV.TO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.52

52W High$13.10

52W Low$0.62

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	N/A	N/A	$2,352.646	$45,166	$60,204
Gross Profit	N/A	N/A	$2,352.646	$45,166	$60,204
Gross Margin	N/A	N/A	100.0%	100.0%	100.0%
Operating Income	$-39,494,000	$-35,682,000	$-27,305,593.024	$-20,000,459.323	$-15,087,773.397
Net Income	$-36,989,000	$-37,496,000	$-27,362,056.526	$-21,897,463.771	$-17,121,502.463
Net Margin	N/A	N/A	-1163033.3%	-48482.2%	-28439.1%
EPS	$-4.43	$-5.05	$-4.10	$-4.41	$-3.91

Company Overview

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Visit Website

Earnings History & Surprises

IMV.TO

Beat Rate

69%

Last 16 quarters

Avg Surprise

+1.8%

EPS vs Estimate

Beats / Misses

11/5

Last 12 quarters

Latest EPS

$-0.99

Q1 2023

EPS Surprise History

Q2 21

+20.6%

$-1.27vs$-1.60

Q3 21

+16.0%

$-1.10vs$-1.31

Q4 21

+1.5%

$-1.30vs$-1.32

Q1 22

-5.3%

$-1.40vs$-1.33

Q2 22

+15.0%

$-1.30vs$-1.53

Q3 22

+11.1%

$-1.20vs$-1.35

Q4 22

+24.1%

$-1.10vs$-1.45

Q1 23

+17.5%

$-0.99vs$-1.20

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2024	Mar 14, 2024	—	—	—	—
Q4 2023	Oct 20, 2023	—	—	—	—
Q3 2023	Aug 18, 2023	$-1.07	—	—	—
Q2 2023	Jun 23, 2023	$-1.07	—	—	—
Q1 2023	Mar 16, 2023	$-1.20	$-0.99	+17.5%	✓ BEAT
Q4 2022	Nov 10, 2022	$-1.45	$-1.10	+24.1%	✓ BEAT
Q3 2022	Aug 11, 2022	$-1.35	$-1.20	+11.1%	✓ BEAT
Q2 2022	May 13, 2022	$-1.53	$-1.30	+15.0%	✓ BEAT
Q1 2022	Mar 17, 2022	$-1.33	$-1.40	-5.3%	✗ MISS
Q4 2021	Nov 10, 2021	$-1.32	$-1.30	+1.5%	✓ BEAT
Q3 2021	Aug 11, 2021	$-1.31	$-1.10	+16.0%	✓ BEAT
Q2 2021	May 12, 2021	$-1.60	$-1.27	+20.6%	✓ BEAT
Q1 2021	Mar 17, 2021	$-1.47	$-1.40	+4.8%	✓ BEAT
Q4 2020	Nov 12, 2020	$-0.90	$-1.30	-44.4%	✗ MISS
Q3 2020	Aug 12, 2020	$-1.80	$-1.30	+27.8%	✓ BEAT
Q2 2020	May 15, 2020	$-1.55	$-1.90	-22.6%	✗ MISS
Q1 2020	Mar 30, 2020	$-1.37	$-1.70	-24.1%	✗ MISS
Q4 2019	Nov 8, 2019	$-1.15	$-1.60	-39.1%	✗ MISS
Q3 2019	Aug 8, 2019	$-1.30	$-1.00	+23.1%	✓ BEAT
Q2 2019	May 9, 2019	$-1.33	$-1.30	+2.3%	✓ BEAT